Check out what’s clicking on FoxBusiness.com.
AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc in a deal worth up to $1.27 billion on Tuesday, in a move to bolster its roster of therapies to treat blood cancers.
At the heart of the deal is the U.S.-based company’s early stage experimental treatment for a form of Non-Hodgkin’s lymphoma, a type of cancer that involves the growth of abnormal white blood cells that can lead to the emergence of tumours.
The Anglo-Swedish drugmaker – whose key blood cancer drug Calquence generated sales of more than $1.2 billion last year – plans to acquire all outstanding equity of TeneoTwo for an upfront payment of $100 million, with additional milestone-related payments of up to $1.17 billion.
TeneoTwo’s experimental drug, TNB-486, belongs to a class of bispecific antibodies that are engineered to redirect the immune system to recognise and kill cancer cells.
US, PFIZER REACH $3.2B COVID VACCINE DEAL
The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. (REUTERS/Rachel Wisniewski)
It is currently in a phase 1 trial in patients with B-cell non-Hodgkin’s lymphoma, who have received 2 or more previous lines of therapy.
MONKEYPOX ISN’T ‘SAME KIND OF VIRUS’ AS COVID, DOCTOR SAYS
AstraZeneca, the biopharmaceutical company, has resumed clinical trials after being cleared by federal health regulators to do so, the company said Friday. (iStock)
The transaction is likely to close in the third quarter of this year and is not expected to impact AstraZeneca’s 2022 outlook, the London-listed company said.
CLICK HERE TO READ MORE ON FOX BUSINESS
TeneoTwo Inc was spun off from Teneobio, which was bought by U.S. biotechnology company Amgen last year.
